Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: AbbVie Inc.

Market Cap 402B 348B 320B 300B 562B 38,244B 570B 3,781B 1,474B 18,615B 1,510B 1,478B 64,453B P/E Ratio 2026 *
27.9x
P/E Ratio 2027 * 20.7x
Enterprise Value 456B 394B 363B 340B 637B 43,364B 647B 4,287B 1,672B 21,107B 1,712B 1,676B 73,082B EV / Sales 2026 *
6.79x
EV / Sales 2027 * 6.14x
Free-Float
95.71%
Yield 2026 *
3.01%
Yield 2027 * 3.18%
1 day+1.32%
1 week+0.22%
Current month+4.60%
1 month+9.22%
3 months+3.66%
6 months+1.97%
Current year-0.33%
1 week 221.16
Extreme 221.165
228.58
1 month 207.68
Extreme 207.68
230.47
Current year 190.75
Extreme 190.75
237.11
1 year 181.73
Extreme 181.73
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 68 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
May. 07Free

Director

1,118 0.0001%
May. 07Free

Director

1,118 0.0001%
May. 07Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+0.22%+19.18%+64.65% 402B
-2.41%+0.14%+38.28%+154.20% 1,010B
+1.07%+3.48%+53.32%+49.85% 580B
+0.77%0.00%+21.28%+16.70% 330B
+0.44%+3.48%+25.65%+35.66% 281B
-0.85%-2.86%+22.54%+14.67% 280B
+1.66%+1.20%-44.35%-47.35% 197B
+0.32%+1.61%+20.32%+60.01% 192B
-0.22%-2.76%+14.19%+60.09% 156B
+0.15%+0.65%+6.81%-34.93% 149B
Average +0.22%+0.82%+17.72%+37.35% 357.83B
Weighted average by Cap. -0.21%+1.02%+26.89%+66.14%

Financials

2026 *2027 *
Net sales 67.23B 58.06B 53.5B 50.08B 93.86B 6,390B 95.31B 632B 246B 3,110B 252B 247B 10,769B 72.71B 62.8B 57.87B 54.17B 102B 6,911B 103B 683B 266B 3,364B 273B 267B 11,647B
Net income 14.85B 12.83B 11.82B 11.07B 20.74B 1,412B 21.06B 140B 54.43B 687B 55.75B 54.56B 2,380B 19.31B 16.68B 15.37B 14.39B 26.96B 1,835B 27.38B 181B 70.75B 893B 72.47B 70.92B 3,093B
Net Debt 53.86B 46.52B 42.87B 40.13B 75.2B 5,120B 76.37B 506B 197B 2,492B 202B 198B 8,628B 44.07B 38.06B 35.07B 32.83B 61.53B 4,189B 62.48B 414B 161B 2,039B 165B 162B 7,059B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-06-12 227.73 $ +1.32% 4,086,503
26-06-11 224.77 $ -0.08% 4,569,353
26-06-10 224.95 $ -0.21% 4,147,303
26-06-09 225.42 $ +1.05% 4,257,921
26-06-08 223.07 $ -1.83% 4,915,633
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
227.73USD
Average target price
253.55USD
Spread / Average Target
+11.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!